S

Stryker

Manufactures orthopedic and surgical medical devices

Project Manager - Breast Care

Full-TimeUpdated
CA$86.7k - CA$115.5k/yr
Mid
Bachelor's
Burnaby, BC, Canada
HybridHybrid position requiring locality to the Burnaby office; travel is 10%.
Project & Program ManagementProject Management

About the job

Requirements
  • A bachelor's degree in Engineering, Science, Physics, or a related field is required.
  • At least 4 years of relevant experience in project management, product development, engineering, quality, operations, or a related technical environment is required.
  • Demonstrated experience leading projects or cross-functional initiatives while managing multiple priorities, timelines, risks, and deliverables is required.
  • Ability to understand technical challenges and translate information into clear project priorities, recommendations, and actions is required.
  • Demonstrated ability to communicate effectively, build cross-functional relationships, solve problems, and drive teams toward decisions and execution is required.
Responsibilities
  • Lead cross-functional teams in planning and executing product updates, enhancements, and sustainment initiatives across the Breast Care portfolio.
  • Manage multiple projects and priorities simultaneously, developing and maintaining project scope, schedules, milestones, deliverables, and resource needs.
  • Partner with R&D, Marketing, Quality, Operations, and other stakeholders to understand customer and business needs, establish priorities, and drive alignment.
  • Identify and manage project risks, dependencies, constraints, and competing priorities while developing clear recommendations and paths forward.
  • Facilitate timely decision-making by helping teams evaluate technical, customer, quality, compliance, cost, and business considerations.
  • Coordinate product and design changes, testing, component replacements, and other initiatives that support product availability, continuity of supply, and the customer experience.
  • Apply sound business judgment to project decisions by considering risk, cost, benefit, resources, and potential business impact.
  • Monitor project progress, communicate changes and status to stakeholders, and proactively address or escalate issues that could impact execution.
  • Ensure projects are executed in accordance with applicable Design Controls, Quality System requirements, and internal procedures.
  • Capture lessons learned and identify opportunities to strengthen project execution and cross-functional ways of working.
Desired Qualifications
  • Experience leading projects within the medical device, healthcare, or another regulated product environment.
  • Experience supporting the development, commercialization, sustainment, or post-market lifecycle of technical products.
  • Working knowledge of Design Controls, Quality Systems, change control, or other regulated product-development processes.
  • Demonstrated business acumen, including experience evaluating project trade-offs involving risk, cost, resources, customer needs, or business impact.
  • Experience with project management and visualization tools such as Microsoft Project, Smartsheet, Planner, Jira, or Power BI.
  • PMP certification or other formal project management training.

About the company

Stryker makes medical devices for hospitals, surgical centers and emergency responders, spanning joint implants, surgical instruments and patient transport equipment. Its Mako platform assists surgeons with joint replacement, while its neurotechnology products support brain and spine procedures and stroke treatment. Clinicians use its equipment during surgery and emergency care, and the company earns money by selling implants, disposable products and capital equipment through direct sales teams and distributors. The business also supplies training and technical support for healthcare providers using its devices. Stryker was founded in 1941 and is headquartered in Portage, Michigan.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kalamazoo, Michigan

Founded

1941

Get referred to Stryker

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Demand supports growth: July 2026 Stryker results show organic sales rose 9%, with reported sales reaching $6.6 billion.
  • Service extends equipment sales: Stryker's ProCare contracts bundle preventive maintenance, repairs and original manufacturer parts.
  • Relocation is available for Worcester technicians: Stryker's live transport service opening also lists 12 paid holidays.

What critics are saying

  • Operational failures reach customers: March 2026 cyberattack disrupted Stryker's ordering, manufacturing and shipping.
  • Older implants retain legal exposure: Stryker's recall estimates include Rejuvenate, LFIT V40 and legacy Wright hip products.
  • Field service demands travel: Stryker's northern Minnesota opening lists 80% travel plus evening or weekend call.

What makes Stryker unique

  • Mako combines imaging and physical guidance: Stryker uses CT-based planning and haptic boundaries during hip replacement.
  • Discarded devices return to service: Stryker's Sustainability Solutions reprocesses medical equipment for hospitals across the U.S. and Canada.
  • Transport extends its technology outside hospitals: Stryker's Power-LOAD supports stretchers while loading and unloading ambulances.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Medical & prescription plans
  • Supplemental health benefits
  • Flexible Spending accounts
  • Employee Assistance Program
  • Short-term & long-term disability
  • Tuition reimbursement
  • 401(k) plan
  • Employee Stock Purchase Plan

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 30th, 2026
Stryker shares fall 10% as 2026 sales guidance is cut to 6.5%-7.0% growth

Stryker shares fell about 10% to $279.98 before the open on Friday, after the medical device maker missed third-quarter estimates and cut its 2026 sales guidance. The stock was already down about 20% this year. Adjusted earnings per share were $3.52 against $3.55 expected. Revenue was $6.52 billion against $6.62 billion expected, up 7.6%. Stryker now expects 2026 organic sales growth of 6.5% to 7.0%, down from 8.3% to 9.3%. Its adjusted EPS guidance fell to $14.80 to $14.90 from $14.95 to $15.10. Chief executive officer Kevin Lobo said the Mako RPS hip and knee system is "off to a slow start." Spencer Stiles succeeds him and will issue the 2027 guidance early next year.

Yahoo Finance
Oct 29th, 2026
Stryker misses Q3 forecasts with $753M profit on $6.52B revenue

Stryker reported third-quarter profit of $753 million, or $1.96 per share, on Thursday. The Michigan-based medical device maker's adjusted earnings, which exclude asset impairment and amortisation costs, were $3.52 per share. Both results missed Wall Street forecasts. Analysts surveyed by Zacks Investment Research expected earnings of $3.56 per share and revenue of $6.58 billion; Stryker posted revenue of $6.52 billion. The company expects full-year earnings of $14.80 to $14.90 per share.

Associated Press
Oct 29th, 2026
Stryker Q3 sales rise 7.7% to $6.5B, but miss expectations; $3B added to buyback

Stryker reported third-quarter net sales of $6.5 billion, up 7.7% from a year earlier. Organic sales also rose 7.7%, driven mainly by higher unit volume. Reported net earnings fell 12.3% to $753 million, or $1.96 per diluted share, down 11.7%. Adjusted earnings per share rose 10.3% to $3.52, and adjusted operating margin rose 60 basis points to 26.2%. MedSurg and Neurotechnology sales grew 9.2% to $3.7 billion. Orthopaedics sales rose 5.7% to $2.9 billion. Chief executive officer Kevin A. Lobo said the results fell short of expectations, but he expects a solid fourth quarter. Stryker now expects 2026 organic sales growth of 6.5% to 7.0% and adjusted earnings per share of $14.80 to $14.90. It bought back $1.0 billion of stock in the quarter, and its board added $3.0 billion to the repurchase programme.

Yahoo Finance
Oct 28th, 2026
Stryker lags peers with 8.5% growth as plant problems, not hospitals, hit sales

Stryker's stock has lost 20.2% over the past 12 months, dividends included, while the S&P 500 returned 15.0%. Its revenue grew 8.5% over the latest four quarters, slower than four of its five peers, including Boston Scientific (13.5%) and Intuitive Surgical (20.5%). Management says hospital demand is steady. It blames the slowdown on a cybersecurity incident that halted manufacturing and on supply problems in peripheral vascular products. First-quarter fiscal 2026 revenue grew just 2.6%, and operating margin fell to 15.5%. Margin recovered to 25.2% in the second quarter. The stock fell 8.8% on September 8, 2026, after the chief financial officer said the vascular issue was unresolved. Third-quarter results are due October 29, 2026. Spencer Stiles will succeed Kevin Lobo as chief executive officer on January 1, 2027.

Stryker Corporation
Oct 27th, 2026
Stryker Completes Acquisition of MAKO Surgical Corp.

Kalamazoo, Michigan - December 17, 2013 - Stryker Corporation (NYSE:SYK) announced today the completion of its previously announced acquisition of MAKO Surgical Corp., a pioneer in the advancement of robotic arm assisted surgery in orthopaedics. "We're excited to welcome MAKO into our organization and combine their expertise in robotic arm assisted surgery with Stryker's innovations in joint reconstruction to further advance the growth of this compelling technology. The long-term potential offered by this technology platform holds the promise of transforming reconstructive surgery, increasing patient satisfaction and enhancing the experience for surgeons and hospitals," said Kevin A. Lobo, President and Chief Executive Officer. As indicated in the September 25, 2013 press release, the transaction is expected to be dilutive to Stryker's adjusted earnings per share excluding acquisition and integration-related charges by approximately $0.10 - $0.12 in the first full year, neutral in